Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07634536 · ClinicalTrials.gov registry record · Phase 2
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
A Phase 2 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07634536: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT07634536 is a Phase 2 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07634536, a Phase 2 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity. Total marrow and lymphoid irradiation (TMLI) is a specialized radiation technique that specifically targets marrow and lymphoid tissue to maximize antitumor efficacy while reducing off target toxicity. Despite these benefits, TMLI is technically challenging and time consuming. The radiation oncology team at Stanford has developed an automated TMLI platform to overcome these challenges. In this phase II trial, automation will be incorporated into a previously validated conditioning regimen of fludarabine/cyclophosphamide/TMLI HCT with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis to confirm the feasibility and safety of automation in patients receiving allogeneic HCT for high-risk myeloid malignancies.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Mycophenolate mofetil (MMF)
- RADIATION VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI)
- BIOLOGICAL Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07634536
The ClinicalTrials.gov registry entry for NCT07634536 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT07634536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07634536 about?
NCT07634536 is a clinical study titled "Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant". Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity. Total marrow and lymphoid irradiation (TMLI) is a specialized radiation technique that specifically...
What is the current status of trial NCT07634536?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-08. Estimated completion is 2028-08.
What interventions are being tested in trial NCT07634536?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Mycophenolate mofetil (MMF) (DRUG), VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI) (RADIATION), Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07634536?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.